NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria.
- 1Department of Internal Medicine, Division of Allergy and Clinical Immunology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye.
Abstract
Background/aim
Data on the course of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity in NSAID-exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well-controlled urticaria.Methods
142 patients with well-controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo-controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment.Results
The median age of the patients was 40 years (IQR 31.5-52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2-8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab (p = 0.001) and untreated groups (p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively.Conclusion
To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well-controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
Related
- Case Report: Hyperactive delirium with psychotic symptoms associated with severe hypothyroidism during pembrolizumab therapy. Complete remission after levothyroxine and no recurrence after pembrolizumab rechallenge
- Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
- Complete remission with single agent lorlatinib in children with ALK+ anaplastic large cell lymphoma and central nervous system involvement: a case report
- The Snoopy Sign Behind a MINOCA: Complete Congenital Absence of the Pericardium.
- A Case of Advanced Hepatocellular Carcinoma with Macrovascular Invasion and Lung Metastases Achieving Pathological Complete Remission Following Sequential Multimodal Therapy: A Case Report.
BibTeX
@article{igde2026nsaid,
title = {{NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria.}},
author = {Merve Hormet Igde and Pelin Korkmaz and Semra Demir and Osman Ozan Yegit and Derya Ünal and Merve Dilşad Atasever and Ayşe Feyza Aslan and Leyla Bölek and Selin Ece Güzel and Nevzat Kahveci and Mehmet Emin Sezgin and Şule Çelik Kamacı and Esra Kaya and Bircan Erden and Asli Gelincik},
journal = {Clinical and translational allergy},
year = {2026},
month = oct,
doi = {10.1002/clt2.70216},
url = {https://europepmc.org/article/MED/42908253},
note = {CC BY},
}
RIS
TY - JOUR
TI - NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria.
AU - Merve Hormet Igde
AU - Pelin Korkmaz
AU - Semra Demir
AU - Osman Ozan Yegit
AU - Derya Ünal
AU - Merve Dilşad Atasever
AU - Ayşe Feyza Aslan
AU - Leyla Bölek
AU - Selin Ece Güzel
AU - Nevzat Kahveci
AU - Mehmet Emin Sezgin
AU - Şule Çelik Kamacı
AU - Esra Kaya
AU - Bircan Erden
AU - Asli Gelincik
PY - 2026
DA - 2026/10/01
JO - Clinical and translational allergy
DO - 10.1002/clt2.70216
UR - https://europepmc.org/article/MED/42908253
AB - Background/aim Data on the course of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity in NSAID-exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well-controlled urticaria.Methods 142 patients with well-controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo-controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment.Results The median age of the patients was 40 years (IQR 31.5-52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2-8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab (p = 0.001) and untreated groups (p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively.Conclusion To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well-controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
SN - 2045-7022
ER -